Pancrelipase for pancreatic disorders: An update

Area of Science:

• Gastroenterology
• Endocrinology
• Pharmacology

Background:

• Pancreatic exocrine insufficiency (PEI) impairs digestion due to insufficient pancreatic enzymes.
• Conditions like cystic fibrosis and chronic pancreatitis cause PEI, leading to malabsorption and malnutrition.
• Pancrelipase, a porcine pancreatic extract, provides essential digestive enzymes: lipases, proteases, and amylases.

Purpose of the Study:

• To review the efficacy and safety of pancrelipase as pancreatic enzyme replacement therapy (PERT) for PEI.
• To highlight recent FDA approvals of pancrelipase formulations based on clinical trial evidence.
• To discuss challenges in PEI diagnosis and the importance of individualized treatment.

Main Methods:

• Review of randomized controlled trials (RCTs) evaluating pancrelipase efficacy.
• Analysis of FDA regulatory decisions regarding pancrelipase products.
• Synthesis of clinical data on the management of pancreatic exocrine insufficiency.

Main Results:

• Pancrelipase formulations (Creon®, Zenpep®, Pancreaze®) are FDA-approved for PEI treatment.
• Pancrelipase effectively reverses steatorrhea, prevents weight loss, and corrects nutritional deficiencies.
• Early diagnosis of PEI remains challenging, necessitating individualized treatment strategies.

Conclusions:

• Pancrelipase is a safe and effective PERT for managing PEI.
• Appropriate use of pancrelipase improves patient outcomes, reduces morbidity, and enhances quality of life.
• Optimizing treatment initiation timing and dosage is crucial for maximal therapeutic benefit.